Kidtrayze

Zinc chloride, potassium iodide, sodium selenite, copper chloride dihydrate, and manganese chloride tetrahydrate, the active ingredients in Kidtrayze, are a trace element supplement presented as an injectable solution for intravenous use. They are intended to correct trace element deficiency in patients requiring parenteral nutrition or who are at risk of micronutrient depletion.

GNH USA supplies Kidtrayze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics across multiple continents worldwide for critical care and emergency medicine.

Kidtrayze supplies essential trace elements for patients with micronutrient deficiencies, supporting metabolic and enzymatic pathways.

Trace element deficiency: replenishes zinc, iodine, selenium, copper and manganese to restore normal enzyme function and antioxidant capacity. Parenteral nutrition support: complements amino acid and carbohydrate solutions, ensuring a complete micronutrient profile for patients receiving intravenous feeding. Critical illness: helps prevent depletion of trace elements during intensive care, aiding immune response and tissue repair. Post‑operative recovery: provides cofactors necessary for wound healing and thyroid hormone synthesis, supporting faster convalescence.

Kidtrayze may be associated with infusion‑related reactions and trace element‑related toxicities.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the infusion site. - Transient nausea: brief feeling of nausea during or shortly after administration. - Mild headache: occasional headache that resolves without intervention. - Fever: low‑grade temperature rise post‑infusion. - Flushing: temporary redness of skin. - Mild dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Copper toxicity: signs include abdominal pain, liver enzyme elevation, and neurological changes. - Severe electrolyte imbalance: abnormal serum levels of zinc, iodine, or manganese leading to cardiac or neurological effects. - Hepatotoxicity: elevated liver enzymes indicating possible liver injury. - Neuropathy: peripheral nerve symptoms such as tingling or numbness. - Renal impairment exacerbation: worsening kidney function due to element accumulation.

Prior to using Kidtrayze, clinicians should observe several precautionary measures to ensure patient safety.

Assess baseline levels: obtain serum zinc, iodine, selenium, copper and manganese before therapy. Monitor electrolytes: regularly check trace element concentrations during treatment. Avoid high‑dose supplements: concurrent trace element products may cause toxicity. Renal impairment: use cautiously as reduced clearance can increase accumulation risk. Hepatic dysfunction: monitor closely because liver disease may affect element metabolism. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kidtrayze can interact with other medications that affect trace element balance, chelation processes, or hormonal pathways, potentially altering efficacy or safety.

Major Interactions (Avoid): - High‑dose copper preparations: may lead to copper overload and toxicity. - Chelating agents (e.g., EDTA, dimercaprol): can bind trace elements and reduce therapeutic effectiveness. - Excess iodine supplements: may cause thyroid dysfunction when combined with Kidtrayze.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: iodine content may influence hormone dosing. - Antioxidant supplements (vitamin C, vitamin E): may modify selenium activity. - Loop diuretics: can alter zinc and manganese excretion, requiring electrolyte monitoring. - Vitamin D analogues: may increase calcium absorption, influencing manganese metabolism; monitor levels.